Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents
- PMID: 16552236
- DOI: 10.1097/01.cco.0000219253.53091.fb
Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents
Abstract
Purpose of review: To provide an update on novel compounds in head and neck cancer (HNC) therapy, with emphasis on biologic agents.
Recent findings: Cisplatin-5-fluorouracil (5-FU) is the standard chemotherapeutic approach in HNC. Strategies to improve its activity include the substitution of 5-FU with oral fluoropyrimidines; the substitution of cisplatin with different analogs or formulations; and the use of additional or alternative compounds. Epidermal growth factor receptor (EGFR) is the most appealing target for novel therapies in HNC. Cetuximab, a chimeric anti-EGFR monoclonal antibody, has undergone evaluation in platinum-refractory recurrent or metastatic HNC with a satisfactory and consistent response rate (10-13%) across three different Phase II studies in association with platinum or as single agent. A recent Phase III placebo-controlled trial has shown better response rate for patients treated with cetuximab and cisplatin, with respect to those treated with cisplatin alone. EGFR tyrosine kinase inhibitors (TKIs) are under investigation in HNC, and efforts are made to understand which molecular features are associated with objective responses. One appealing way to use EGFR TKIs is in combination with other biologic compounds, such as anti-angiogenic agents.
Summary: New molecular-targeted therapies are inducing consistent, small improvements in HNC management. The major challenge regards how to better combine them with the final aim of obtaining long-term stabilization of advanced disease.
Similar articles
-
Emerging drugs for head and neck cancer.Expert Opin Emerg Drugs. 2004 May;9(1):91-104. doi: 10.1517/eoed.9.1.91.32953. Expert Opin Emerg Drugs. 2004. PMID: 15155138 Review.
-
Molecular targeted therapy of head and neck cancer: review and clinical development challenges.Eur J Cancer. 2007 Nov;43(17):2457-66. doi: 10.1016/j.ejca.2007.08.016. Epub 2007 Sep 27. Eur J Cancer. 2007. PMID: 17904355 Review.
-
Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.Exp Biol Med (Maywood). 2010 Aug;235(8):907-20. doi: 10.1258/ebm.2009.009181. Epub 2010 Jun 18. Exp Biol Med (Maywood). 2010. PMID: 20562132 Review.
-
Emerging molecular targeted therapies in the treatment of head and neck cancer.Expert Opin Emerg Drugs. 2009 Jun;14(2):299-310. doi: 10.1517/14728210902997947. Expert Opin Emerg Drugs. 2009. PMID: 19519286 Review.
-
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.Curr Opin Oncol. 2008 May;20(3):256-63. doi: 10.1097/CCO.0b013e3282f9b575. Curr Opin Oncol. 2008. PMID: 18391623 Review.
Cited by
-
Huanglianjiedu Decoction as an effective treatment for oral squamous cell carcinoma based on network pharmacology and experimental validation.Cancer Cell Int. 2021 Oct 21;21(1):553. doi: 10.1186/s12935-021-02201-6. Cancer Cell Int. 2021. PMID: 34674717 Free PMC article.
-
TNM staging with FDG-PET/CT in patients with primary head and neck cancer.Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1953-62. doi: 10.1007/s00259-007-0564-5. Epub 2007 Aug 24. Eur J Nucl Med Mol Imaging. 2007. PMID: 17717661
-
TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma.Am J Cancer Res. 2020 Feb 1;10(2):454-472. eCollection 2020. Am J Cancer Res. 2020. PMID: 32195020 Free PMC article.
-
Focus on HPV Infection and the Molecular Mechanisms of Oral Carcinogenesis.Viruses. 2021 Mar 26;13(4):559. doi: 10.3390/v13040559. Viruses. 2021. PMID: 33810374 Free PMC article. Review.
-
Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer.Mol Cancer Ther. 2012 Nov;11(11):2401-9. doi: 10.1158/1535-7163.MCT-12-0448. Epub 2012 Sep 12. Mol Cancer Ther. 2012. PMID: 22973056 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
